ARTL on Nasdaq

ARTELO BIOSCIENCES, INC.

Price unavailable

Last updated Oct 16, 2026.

Overview

Compare with another stock.

  • TickerARTL on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersNV
  • Incorporated inNV2
  • Business address505 Lomas Santa Fe, Suite 160, Solana Beach, Ca 920752
  • Filer categoryNon-accelerated filer, Smaller reporting company2

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income345678-$11.4M in 2025+255% since 2019
-$15.0M-$10.0M-$5.0M02019: -$3.2M-$3.2M20192020: -$4.7M-$4.7M2020+46%2021: -$9.4M-$9.4M2021+101%2022: -$10.3M-$10.3M2022+9%2023: -$9.9M-$9.9M2023−3%2024: -$10.1M-$10.1M2024+2%2025: -$11.4M-$11.4M2025+13%
Net income345678-$12.9M in 2025+493% since 2019
-$15.0M-$10.0M-$5.0M02019: -$2.2M-$2.2M20192020: -$4.7M-$4.7M2020+114%2021: -$9.4M-$9.4M2021+102%2022: -$10.1M-$10.1M2022+7%2023: -$9.3M-$9.3M2023−8%2024: -$9.8M-$9.8M2024+6%2025: -$12.9M-$12.9M2025+31%

Every line of the income statement in the latest annual report, as filed.8

Period ending2025-12-312024-12-31
General and administrative$6.0M$4.1M
Research and development$5.4M$6.0M
Total Operating Expenses$11.4M$10.1M
Loss from Operations-$11.4M-$10.1M
Gain on investment$22.0K$0
Interest expense-$194.0K$0
Interest expense - related party-$83.0K$0
Loss on extinguishment of debt-$825.0K$0
Loss on extinguishment of debt - related party-$333.0K$0
Net change in fair value of digital assets-$62.0K$0
Net change in fair value of trading marketable securities$0$282.0K
Total other (expense) income-$1.5M$282.0K
Provision for income taxes$0$0
NET LOSS-$12.9M-$9.8M
Foreign currency translation adjustments-$70.0K$1.0K
Total Other Comprehensive Income (Loss)-$70.0K$1.0K
TOTAL COMPREHENSIVE LOSS-$12.9M-$9.8M
Basic and Diluted Loss per Common Share-$12.52-$18.30
Basic and Diluted Weighted Average Common Shares Outstanding1.0M shares537.0K shares

Compare ARTELO BIOSCIENCES, INC. with another company

Former names

  • REACTIVE MEDICAL INC.Feb 10, 2017 to Apr 17, 20172
  • KNIGHT KNOX DEVELOPMENT CORP.Oct 8, 2014 to Feb 6, 20172

Recent filings

  1. Oct 9, 20268-K
  2. Aug 27, 20268-K
  3. Aug 20, 202610-Q/A
  4. Aug 14, 2026SCHEDULE 13G/A
  5. Aug 13, 2026SCHEDULE 13G/A
  6. Aug 12, 202610-Q
  7. Jul 21, 20264
  8. Jul 21, 20264
  9. Jul 21, 20264
  10. Jul 21, 20264
  11. Jul 21, 20264
  12. Jul 21, 20264
  13. Jul 17, 20268-K
  14. Jul 16, 2026DEFA14A
  15. Jul 16, 2026DEFA14A

Every filing from the last three years, summarized. The full record is on SEC EDGAR.1